Perpetual pharmaceutical pearl provider

ABN401 is the tyrosine kinase inhibitor agent that targets c-Met. In cancer, c-Met triggers tumor growth and angiogenesis. Recently, it revealed that c-Met is related to a poor prognosis in cancers. Furthermore, the c-Met mutation is the largest portion of EGFR TKI resistance mechanisms. ABN401 shows a superior safety profile in the Phase I clinical trial. We aim to provide the safest targeted therapy to NSCLC patients with Met mutation.

ABN501 is a novel Claudin 3(CLDN3) targeting monoclonal antibody with high specificity and strong binding affinity. Antibody-dependent cellular cytotoxicity (ADCC) activity against CLDN3-positive tumors was tested in vitro and in vivo. The pre-clinical trial is planned for 2023.

ABION is developing broad spectrum anti-viral inhaler drug based an 2nd generation Interferon-β. Our goal is to prevent infected patients from severity and hospitalization, improving patient convenience by stockpiling & distributing in the early phase of pandemic.